Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients. 1994

P Jungers, and P Chauveau, and A M Couroucé, and P Devillier, and J L Excler, and F Bailleux, and P Saliou
Department of Nephrology, Necker Hospital, Paris, France.

Immunogenicity of the recombinant GenHevac B vaccine (G), containing both the S and the preS2 antigen, was compared with that of the plasma-derived Hevac B (H) vaccine in 120 chronic uremic predialysis patients. Sixty received 20 micrograms/dose of G and 60 received 5 micrograms/dose of H at 0, 1, 2, 4, and 12 months. Two months after the fourth injection, seroconversion (antibody to hepatitis B surface antigen [HBs], > or = 2 mIU/mL) was seen in 85% of group G and 67% of group H patients (P < .02); seroprotection (anti-HBs, > or = 10 mIU/mL) was seen in 71% and 59%, respectively. The geometric mean titers (GMT) of anti-HBs in responders were 112 and 229 mIU/mL, respectively. After booster injection at month 12, seroconversion occurred in 94% and 76% and seroprotection in 84% and 70%, with anti-HBs GMTs of 879 and 1001 mIU/mL in groups G and H, respectively. The recombinant GenHevac B vaccine elicited seroconversion and seroprotection in a higher proportion of chronic uremic patients, with comparably high anti-HBs antibody titers in responders.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006510 Hepatitis B Antibodies Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens. Anti-Australia Antigens,Anti-HBAg,Anti-Hepatitis B Antigens,Anti HBAg,Hepatitis B Virus Antibodies,Anti Australia Antigens,Anti Hepatitis B Antigens,Antibodies, Hepatitis B,Antigens, Anti-Australia,Antigens, Anti-Hepatitis B,B Antibodies, Hepatitis,B Antigens, Anti-Hepatitis,HBAg, Anti
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014511 Uremia A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms. Uremias

Related Publications

P Jungers, and P Chauveau, and A M Couroucé, and P Devillier, and J L Excler, and F Bailleux, and P Saliou
February 1989, Revue de l'infirmiere,
P Jungers, and P Chauveau, and A M Couroucé, and P Devillier, and J L Excler, and F Bailleux, and P Saliou
June 1993, Asian Pacific journal of allergy and immunology,
P Jungers, and P Chauveau, and A M Couroucé, and P Devillier, and J L Excler, and F Bailleux, and P Saliou
January 1992, Annali dell'Istituto superiore di sanita,
P Jungers, and P Chauveau, and A M Couroucé, and P Devillier, and J L Excler, and F Bailleux, and P Saliou
January 2000, Hepatology (Baltimore, Md.),
P Jungers, and P Chauveau, and A M Couroucé, and P Devillier, and J L Excler, and F Bailleux, and P Saliou
January 1986, Journal of hepatology,
P Jungers, and P Chauveau, and A M Couroucé, and P Devillier, and J L Excler, and F Bailleux, and P Saliou
February 1985, Lancet (London, England),
P Jungers, and P Chauveau, and A M Couroucé, and P Devillier, and J L Excler, and F Bailleux, and P Saliou
January 1989, Acta medica Iugoslavica,
P Jungers, and P Chauveau, and A M Couroucé, and P Devillier, and J L Excler, and F Bailleux, and P Saliou
January 1987, Postgraduate medical journal,
P Jungers, and P Chauveau, and A M Couroucé, and P Devillier, and J L Excler, and F Bailleux, and P Saliou
January 1992, American journal of nephrology,
P Jungers, and P Chauveau, and A M Couroucé, and P Devillier, and J L Excler, and F Bailleux, and P Saliou
January 1985, Lancet (London, England),
Copied contents to your clipboard!